BACKGROUND: Renal failure requiring dialysis in the setting of hospitalization for serious illness is a poor prognostic sign, and dialysis and aggressive care are sometimes withheld. OBJECTIVE: To evaluate the clinical outcomes and cost-effectiveness of initiating dialysis and continuing aggressive care for seriously ill hospitalized patients. DESIGN: Prospective cohort study and cost-effectiveness analysis. SETTING: Five geographically diverse teaching hospitals. PATIENTS: 490 patients (median age, 61 years; 58% women) enrolled in the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments (SUPPORT) in whom dialysis was initiated. MEASUREMENTS: Survival, functional status, quality of life, and health care costs. Life expectancy was estimated by extrapolating survival data (up to 4.4 years of follow-up) using a declining exponential function. Utilities (quality-of-life weights) were estimated by using time-tradeoff questions. Costs were based on data from SUPPORT and published Medicare data. RESULTS: Median duration of survival was 32 days, and only 27% of patients were alive after 5 months. Survivors reported a median of one dependency in activities of daily living, and 62% rated their quality of life as "good" or better. Overall, the estimated cost per quality-adjusted life-year saved by initiating dialysis and continuing aggressive care rather than withholding dialysis and allowing death to occur was $128,200. For the 103 patients in the worst prognostic category, the estimated cost per quality-adjusted life-year was $274,100; for the 94 patients in the best prognostic category, the cost per quality-adjusted life-year was $61,900. CONCLUSIONS: For the few patients who survived, clinical outcomes were fairly good. With the exception of patients with the best prognoses, however, the cost-effectiveness of initiating dialysis and continuing aggressive care far exceeded $50,000 per quality-adjusted life-year, a commonly cited threshold for cost-effective care.
BACKGROUND:Renal failure requiring dialysis in the setting of hospitalization for serious illness is a poor prognostic sign, and dialysis and aggressive care are sometimes withheld. OBJECTIVE: To evaluate the clinical outcomes and cost-effectiveness of initiating dialysis and continuing aggressive care for seriously ill hospitalized patients. DESIGN: Prospective cohort study and cost-effectiveness analysis. SETTING: Five geographically diverse teaching hospitals. PATIENTS: 490 patients (median age, 61 years; 58% women) enrolled in the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments (SUPPORT) in whom dialysis was initiated. MEASUREMENTS: Survival, functional status, quality of life, and health care costs. Life expectancy was estimated by extrapolating survival data (up to 4.4 years of follow-up) using a declining exponential function. Utilities (quality-of-life weights) were estimated by using time-tradeoff questions. Costs were based on data from SUPPORT and published Medicare data. RESULTS: Median duration of survival was 32 days, and only 27% of patients were alive after 5 months. Survivors reported a median of one dependency in activities of daily living, and 62% rated their quality of life as "good" or better. Overall, the estimated cost per quality-adjusted life-year saved by initiating dialysis and continuing aggressive care rather than withholding dialysis and allowing death to occur was $128,200. For the 103 patients in the worst prognostic category, the estimated cost per quality-adjusted life-year was $274,100; for the 94 patients in the best prognostic category, the cost per quality-adjusted life-year was $61,900. CONCLUSIONS: For the few patients who survived, clinical outcomes were fairly good. With the exception of patients with the best prognoses, however, the cost-effectiveness of initiating dialysis and continuing aggressive care far exceeded $50,000 per quality-adjusted life-year, a commonly cited threshold for cost-effective care.
Entities:
Keywords:
Death and Euthanasia; Empirical Approach; Health Care and Public Health; Professional Patient Relationship; Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments (SUPPORT)
Authors: Kirsten L Johansen; Mark W Smith; Mark L Unruh; Andrew M Siroka; Theresa Z O'Connor; Paul M Palevsky Journal: Clin J Am Soc Nephrol Date: 2010-05-27 Impact factor: 8.237
Authors: Ezra Gabbay; Jose Calvo-Broce; Klemens B Meyer; Thomas A Trikalinos; Joshua Cohen; David M Kent Journal: J Gen Intern Med Date: 2010-07-20 Impact factor: 5.128
Authors: Vilija R Joyce; Mark W Smith; Kirsten L Johansen; Mark L Unruh; Andrew M Siroka; Theresa Z O'Connor; Paul M Palevsky Journal: Clin J Am Soc Nephrol Date: 2012-05-17 Impact factor: 8.237
Authors: Morgan E Grams; Sushrut S Waikar; Blaithin MacMahon; Seamus Whelton; Shoshana H Ballew; Josef Coresh Journal: Clin J Am Soc Nephrol Date: 2014-01-23 Impact factor: 8.237
Authors: Sean M Bagshaw; Neill K J Adhikari; Karen E A Burns; Jan O Friedrich; Josée Bouchard; Francois Lamontagne; Lauralyn A McIntrye; Jean-François Cailhier; Peter Dodek; Henry T Stelfox; Margaret Herridge; Stephen Lapinsky; John Muscedere; James Barton; Donald Griesdale; Mark Soth; Althea Ambosta; Gerald Lebovic; Ron Wald Journal: Clin J Am Soc Nephrol Date: 2019-03-21 Impact factor: 8.237